by Lyla El-Fayomi | Mar 12, 2026
Somehow we are already into March, and spring – at least in some places – feels close by. To catch you up, I’ve put together a recap of some of the research that scientists were buzzing about in the field of regenerative medicine from 2025; I cover the good, the bad,...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Lyla El-Fayomi | Jul 17, 2025
The volume of clinical updates I encounter every month is steadily but very noticeably growing month over month! There are lots to get through, so in this rapid-fire edition of RMNU🔬, you’ll find short summaries on all the biggest headlines of the summer’s first half....
by Stacey Johnson | Jun 24, 2025
Pink. What does the colour pink make you think of? It might make you think of activism, acceptance, awareness and allyship based on how it has been adopted by various groups around the world. Pink makes me think of the American singer, songwriter and activist P!nk....
by Kevin Robb | May 22, 2025
For the first time, mesenchymal stromal cells (MSCs) can be used in routine clinical practice under the nod of regulatory approval in the United States. The MSC product known as Ryoncil was made available to patients in March 2025 following a historic decision from...
by Lyla El-Fayomi | May 16, 2025
In this edition of RMNU🔬, we’re keeping up with multiple research advances in the vision repair field. Also, Vertex Pharmaceuticals is dropping a big therapeutic from their portfolio, and Longeveron has a new publication. Of course, yet another round of updates on...
Comments